MAP2K7 and metastatic melanoma: Combination BRAF/MEK inhibitor therapy has improved the progression‐free and overall survival of patients with BRAFV600 mutant metastatic melanoma relative to either dacarbazine or single agent BRAFi therapy [23, 24].